Apogenix AG

Biotechnology - Therapeutics and Diagnostics

Immunotherapy I Proteins

Apogenix has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. These protein therapeutics target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response, and thus have the potential to transform the treatment of oncological and malignant hematological diseases. The company’s lead immuno-oncology candidate, asunercept, is in late-stage clinical development for the treatment recurrent glioblastoma, the most frequent and aggressive brain tumor.  Apogenix’ scientific team has developed the proprietary HERA-ligand technology platform for the development of novel fusion proteins. In 2017, AbbVie initiated a phase I trial with this HERA-TRAIL receptor agonist (ABBV-621) in patients suffering from solid tumors, non-Hodgkins ́s lymphoma, or acute myeloid leukemia.


BioRN Network e.V.

Im Neuenheimer Feld 582

D-69120 Heidelberg

Contact us >>


BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations, supporting a rich translational ecosystem and promoting, representing and connecting the regional innovation stakeholders.

  • LinkedIn Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon

"Making Life Science matter...

...and Innovation happen!"


© Copyright - BioRN Network e.V. -  Imprint & Legal Notice - Data Privacy Policy